Serina Therapeutics, Inc. SER

SER Company Overview

Serina Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing drug candidates that leverage its proprietary polymer technology platform to improve the delivery, tolerability, and pharmacokinetic profile of therapeutics. The company operates within the biopharmaceutical and central nervous system (CNS) therapeutics industries, with a primary emphasis on neurology and other indications where sustained drug exposure and reduced toxicity may provide clinical advantages. Its core technology platform, known as POZ Platform™, is based on a synthetic, water-soluble polymer designed as an alternative to polyethylene glycol (PEG) for drug conjugation and delivery applications.

The company’s primary business activities center on advancing internally developed therapeutic candidates and evaluating broader applications of the POZ Platform™ through potential collaborations and licensing opportunities. Serina’s lead development efforts have focused on CNS-related disorders, including Parkinson’s disease, through reformulated or optimized therapeutic approaches intended to improve patient outcomes. The company evolved from earlier polymer science and drug-delivery research efforts and has repositioned itself as a therapeutics-focused biotechnology company through public-market financing activities, strategic restructuring, and technology platform development.